Compare CMTL & IBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CMTL | IBIO |
|---|---|---|
| Founded | 1967 | 2008 |
| Country | United States | United States |
| Employees | 817 | N/A |
| Industry | Radio And Television Broadcasting And Communications Equipment | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 52.7M | 52.8M |
| IPO Year | 2024 | 2009 |
| Metric | CMTL | IBIO |
|---|---|---|
| Price | $1.19 | $0.75 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 9 |
| Target Price | $3.63 | ★ $5.69 |
| AVG Volume (30 Days) | 299.1K | ★ 646.8K |
| Earning Date | 12-10-2026 | 11-16-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 66.76 | ★ 81.71 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $249,613,000.00 | N/A |
| Revenue This Year | $6.27 | N/A |
| Revenue Next Year | $4.14 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $1.14 | $0.69 |
| 52 Week High | $6.21 | $3.82 |
| Indicator | CMTL | IBIO |
|---|---|---|
| Relative Strength Index (RSI) | 36.96 | 37.87 |
| Support Level | $1.15 | $0.71 |
| Resistance Level | $1.53 | $1.52 |
| Average True Range (ATR) | 0.07 | 0.07 |
| MACD | -0.01 | 0.02 |
| Stochastic Oscillator | 16.00 | 33.63 |
Comtech Telecommunications Corp is a provider of communications technology and solutions. It operates in two reportable business segments: Satellite and Space Communications and Allerium. The company's Satellite and Space Communications segment, which generates maximum revenue, is organized into four technology areas: satellite modem and amplifier technologies, troposcatter technologies, cybersecurity training, and space components. This segment designs and manufactures modems, amplifiers, traveling wave tube amplifiers, frequency converters, and offers other associated software and services. The Allerium segment provides next-generation 911 (NG-911) infrastructure and solutions for state and local governments and carriers. Geographically, the company derives its key revenue from the USA.
iBio Inc is a clinical-stage biotechnology company using Artificial Intelligence (AI) for the development of hard-to-drug precision antibodies for obesity, cardiometabolic, and cardiopulmonary diseases. Its product candidate pipeline includes IBIO-610, a monoclonal antibody designed to block Activin E; IBIO-800, a bispecific antibody program targeting myostatin, growth differentiation factor 11 (GDF11), and Activin A; IBIO-600; Amylin Antibody; and Target 4, in different stages of development, being developed as potential therapies for obesity and cardiometabolic disease. The company operates as one reportable segment, which is that of a biotechnology company leveraging AI and ML for the development of hard-to-drug precision antibodies.